Punicalagin Exerts Protective Effects against Ankylosing Spondylitis by Regulating NF-κB-TH17JAK2STAT3 Signaling and Oxidative Stress

Abstract EN

Background.

Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by sacroiliitis and spinal rigidity of the axial joints.

The role of oxidative stress and increased proinflammatory cytokines is well documented in AS pathogenesis.

Punicalagin (2,3-hexahydroxydiphenoyl-gallagyl-D-glucose), an ellagitannin widely present in pomegranates, is found to exhibit potent anti-inflammatory, antiproliferative, and antioxidative effects.

The present study was undertaken to investigate the effects of punicalagin in a rodent model of AS.

Methods.

BALB/c mice induced spondylitis were sacrificed 24 h after the last injection of proteoglycan extract.

Histological scoring was done to assess the degree of the disease.

The expression of JAK2/STAT3 proteins and proteins of the nuclear factor-κB (NF-κB) pathway was determined by immunoblotting.

Serum levels of inflammatory mediators—TNF-α, IL-1β, IL-6, IL-17A, and IL-23—were assessed.

Levels of lipid peroxidation and reactive oxygen species (ROS) were quantified.

Antioxidant status as a measure of activities of antioxidant enzymes—catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD)—was determined.

Results.

Punicalagin effectively improved antioxidant status and decreased lipid peroxidation, ROS production, and serum levels of inflammatory mediators.

NF-κB pathway and JAK2/STAT3 signaling were significantly (p<0.05) downregulated.

Punicalagin effectively regulated the production of cytokines by the Th17 cells and the IL-17A/IL-23 axis.

Conclusion.

The observations suggest that punicalagin exerts a protective role in AS via reducing oxidative stress and regulating NF-κB/TH17/JAK2/STAT3 signal.

Punicalagin thus could be explored further as a potent candidate compound in the treatment of AS.